10x Genomics (TXG) CEO Serge Saxonov Sells 18,545 Shares

What Happened
Serge Saxonov, CEO of 10x Genomics, sold 18,545 shares on August 24, 2026, for total gross proceeds of approximately $1,168,775. The sale was executed in multiple open-market trades at prices ranging from $63.0088 to $63.78; the reported weighted-average sale price is $63.02. According to the filing, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-08-24 (reported on Form 4 filed 2026-08-26) — filing appears to be within the normal Form 4 timing.
• Transaction type: Sale (code S); purpose: tax withholding on vested RSUs (footnote F1).
• Shares sold: 18,545; weighted-average price: $63.02; proceeds ≈ $1,168,775. Price range across trades: $63.0088–$63.78 (footnote F2).
• Shares held by trusts: Some shares involved are held by the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, for which Saxonov serves as trustee (footnotes F3–F5).
• The reporting person offers to provide a breakdown of shares sold at each separate sale price upon request (footnote F2).
• Shares owned after the transaction are not stated in the provided excerpt of the filing.

Context
The filing specifies this was a sell-to-cover transaction to satisfy tax withholding on RSU vesting — a routine, administrative sale rather than a directional investment purchase. For retail investors, purchases by insiders are often considered stronger signals of confidence than routine sales; this transaction alone should not be taken as an indicator of a change in management’s view of the company.